Anixa Biosciences entered into a development and manufacturing agreement with Cytovance Biologics to produce cGMP clinical materials for its Phase 2 breast cancer vaccine trial. The agreement, announced on April 1 2026, gives Anixa the capacity to manufacture the vaccine under the cGMP conditions required for regulatory approval.
The partnership is a critical operational milestone that enables the company to move the vaccine from preclinical and Phase 1 stages into the next clinical phase. By outsourcing manufacturing to a CDMO that specializes in mammalian and microbially expressed biologics, Anixa can maintain its lean operating model while ensuring that high‑quality clinical supply is available for the planned trial.
The vaccine targets α‑lactalbumin, a protein that re‑emerges in many breast cancers and is the focus of Anixa’s preventive and therapeutic immunotherapy strategy. Phase 1 data, presented in December 2025, met all primary endpoints, demonstrated safety and tolerability at the maximum tolerated dose, and produced protocol‑defined immune responses in 74 % of participants. The program was developed in collaboration with the Cleveland Clinic and is built on preclinical research led by the late Vincent Tuohy, Ph.D.
Dr. Amit Kumar, Chairman and CEO of Anixa, said, “With final Phase 1 data demonstrating safety, tolerability, and strong immune responses in 74 % of participants, we are focused on advancing this program toward Phase 2. Our agreement with Cytovance represents an important operational milestone as we work to secure cGMP clinical supply for the next stage of development.” Ping Zhang, CEO of Cytovance, added, “We are pleased to partner with Anixa to manufacture clinical materials for its Phase 2 breast cancer vaccine trial. Our team is committed to delivering high‑quality cGMP manufacturing solutions that support innovative biotech programs. We look forward to leveraging our development and production capabilities to help advance this promising immunotherapy candidate.”
The agreement positions Anixa to initiate the Phase 2 trial and may attract licensing interest from larger pharmaceutical companies. The partnership also underscores the company’s strategy of leveraging external expertise to accelerate development while preserving capital. With a robust manufacturing partner in place, Anixa can focus on clinical execution and regulatory strategy as it moves toward potential regulatory approval and market entry.
Anixa plans to begin Phase 2 enrollment in the first half of 2027, with Cytovance expected to deliver the first batch of clinical vaccine material by the end of 2026. The company will provide further updates on trial initiation and manufacturing progress in upcoming investor communications.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.